Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities

Circ Res. 2017 Aug 18;121(5):499-501. doi: 10.1161/CIRCRESAHA.117.311532.
No abstract available

Keywords: angina, unstable; cholesterol, LDL; insurance, health; patient care; secondary prevention.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Humans
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Hypolipidemic Agents / chemistry
  • Hypolipidemic Agents / pharmacology
  • Hypolipidemic Agents / therapeutic use*
  • PCSK9 Inhibitors*
  • Proprotein Convertase 9 / metabolism*

Substances

  • Antibodies, Monoclonal
  • Enzyme Inhibitors
  • Hypolipidemic Agents
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9